anaerobes

Sulconazole mononitrate (Exelderm) is the nitrate salt form of sulconazole, a synthetic imidazole derivative with the antifungal property. Sulconazole mononitrate inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols and inhibition of the synthesis of ergosterol, an important component of the fungal cell membrane. Inhibition of ergosterol synthesis leads to a disruption of cell membrane permeability, and ultimately inhibition of cell wall synthesis. In addition, Sulconazole mononitrate seems to interfere with the autolytic degradation of fungal DNA and RNA.

Ertapenem sodium (MK-826) is a new long-acting 1-β-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum β-lactamases.

Ecenofloxacin HCl, the salt form of Ecenofloxacin, is a novel fluoroquinolone antibiotic exhibiting potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobes.

YM-17K (MC-352) is a macrolide antibiotic. It exhibits antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobes. The activity of YM-17K is stable in serum and is minimally affected by pH levels.

Ranbezolid (RBx7644 free base) is an orally effective oxazolidinone antibiotic targeting Gram-positive and Gram-negative anaerobes, such as Staphylococcus aureus, Staphylococcus epidermidis, and Bacteroides fragilis. It inhibits the 50S ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid also disrupts cell wall and lipid synthesis. This compound acts rapidly as a bactericidal agent, significantly reducing bacterial load while offering improved cardiovascular safety. Ranbezolid is applicable in research on antibiotics against anaerobic bacteria.

BU-2313 A is a new antibiotic complex. It also active against anaerobes.

Faropenem, a highly efficacious and orally bioavailable beta-lactam antibiotic, exhibits an extensive range of in vitro antimicrobial activity against diverse gram-positive and -negative aerobes and anaerobes. Notably, Faropenem possesses inherent resistance to hydrolysis by virtually all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Moreover, Faropenem has been developed as an oral prodrug, namely faropenem medoxomil, for the investigation of respiratory tract infections.

Isepamicin (Sch 21420) is a potent aminoglycoside antibacterial compound with enhanced efficacy against strains harboring type I 6'-acetyltransferase. Its antibacterial spectrum encompasses Enterobacteriaceae and staphylococci, while exhibiting resistance against anaerobes, Neisseriaceae, and streptococci. Moreover, Isepamicin displays a robust concentration-dependent bactericidal effect, a prolonged post-antibiotic effect lasting several hours, and is capable of inducing adaptive resistance.

Gepotidacin hydrochloride, also known as GSK-2140944 hydrochloride, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin hydrochloride is a novel antibacterial drug candidate. Gepotidacin hydrochloride Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin hydrochloride is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, Gepotidacin hydrochloride inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively.

Balhimycin, a glycopeptide antibiotic produced through the fermentation broth of Amycolatopsis sp., exhibits anti-bacterial effects against staphylococci and anaerobes [1].

Porothramycin B is an antibiotic with activity against Gram-positive bacteria and anaerobes.

Sulfite Agar is suitable for the tube count of sulfite-reducing anaerobes. The composition of 1 liter of the medium is 31 g Sulfite Agar.